What is the optimal first-line regimen for advanced non-small cell lung cancer patients with epidermal growth factor receptor mutation: a systematic review and network meta-analysis.

Abstract excerpt

OBJECTIVES: There are currently various tyrosine kinase inhibitor (TKI)-based regimens available, and it can be challenging for clinicians to determine the most effective and safe option due to the lack of direct comparisons between these regimens. In this study, we conducted a network meta-analysis comparing the efficacy and safety of distinct regimens to determine the optimal regimen for patients with...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acrylamides
• Share to Antineoplastic Combined Chemotherapy Protocols